AstraZeneca Pharma India Regulatory Approval

Capacity Expansion

AstraZeneca Pharma India Capacity Expansion

AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.

office space

25600.0 sq ft

Annual General Meeting

AstraZeneca Pharma India Annual General Meeting

AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.

Other Announcement

AstraZeneca Pharma India Other Announcement

NSE Sustainability Ratings and Analytics assigned AstraZeneca Pharma India an ESG rating of 73 for FY 2025-26. The rating was independently prepared without company engagement.

Legal & Regulatory

AstraZeneca Pharma India Legal & Regulatory

AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.

Value

₹0.03 Cr

From

Registrar of Companies, Bengaluru, Karnataka

Legal & Regulatory

AstraZeneca Pharma India Legal & Regulatory

AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.

Value

₹0.02 Cr

Management Change

AstraZeneca Pharma India Management Change

AstraZeneca Pharma India's Dr. Sandeep Arora resigned as Director, Medical Affairs, effective September 15, 2026. The company is seeking a suitable replacement for the position.

Regulatory ApprovalVedavaag Systems Ltd VEDAVAAG

Vedavaag Systems Regulatory Approval

Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.

Regulatory ApprovalHikal Ltd HIKALAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Hikal Regulatory Approval

Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.

Regulatory ApprovalSun Pharmaceutical Industries Ltd SUNPHARMAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sun Pharmaceutical Industries Regulatory Approval

Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.

Regulatory ApprovalRNFI Services Ltd RNFIAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

RNFI Services Regulatory Approval

RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.